Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эректильная дисфункция: особенности диагностики и медикаментозного лечения мужчин с сопутствующими заболеваниями
Эректильная дисфункция: особенности диагностики и медикаментозного лечения мужчин с сопутствующими заболеваниями
Корнеев И.А. Эректильная дисфункция: особенности диагностики и медикаментозного лечения мужчин с сопутствующими заболеваниями. Consilium Medicum. 2015; 17 (7): 24–28. DOI: 10.26442/2075-1753_2015.7.24-28
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Эректильная дисфункция (ЭД) распространена среди мужского населения и тесно связана с наличием сопутствующих заболеваний. Мужчины с ЭД нуждаются в комплексном обследовании и требуют междисциплинарного подхода для получения оптимальных результатов терапии. Ингибиторы фосфодиэстэразы 5-го типа и, в частности, препарат силденафил, являются эффективными и безопасными препаратами 1-й линии для лечения мужчин с ЭД разной этиологии, открываются перспективные направления использования этих препаратов при сопутствующих урологических заболеваниях.
Ключевые слова: эректильная дисфункция, ингибиторы фосфодиэстеразы 5-го типа.
Ключевые слова: эректильная дисфункция, ингибиторы фосфодиэстеразы 5-го типа.
________________________________________________
Erectile dysfunction (ED) is common among the male population and is closely linked to the presence of comorbidities. Men with erectile dysfunction need a comprehensive examination and require a multidisciplinary approach for optimal results of therapy. Phosphodiesterase type 5 inhibitors, and in particular the drug sildenafil, are effective and safe 1st-line treatment drugs for men with ED of various etiologies, open up promising areas of use of these drugs in patients with concomitant urological diseases.
Key words: erectile dysfunction, phosphodiesterase type 5.
Key words: erectile dysfunction, phosphodiesterase type 5.
Полный текст
Список литературы
1. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58 (13): 1378–85.
2. Gazzaruso C, Coppola A, Montalcini T et al. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 2011; 40 (2): 273–9.
3. Корнеев И.А., Алексеева Т.А., Аль-Шукри С.Х. и др. Детерминанты риска развития эректильной дисфункции мужчин в Российской Федерации: анализ результатов эпидемиологического исследования. Урология. 2014; 3: 26–31. / Korneev I.A., Alekseeva T.A., Al'-Shukri S.Kh. i dr. Determinanty riska razvitiia erektil'noi disfunktsii muzhchin v Rossiiskoi Federatsii: analiz rezul'tatov epidemiologicheskogo issledovaniia. Urologiia. 2014; 3: 26–31. [in Russian]
4. Nehra A, Jackson G, Miner M et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87 (8): 766–78
5. Cheitlin MD. Sexual activity and cardiac risk. Am J Cardiol 2005; 96: 24M–28M.
6. Kostis J, Jackson G, Rosen R et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96 (2): 313–21.
7. Guay AT. Optimizing response to phosphodiesterase therapy: impact of risk-factor management. J Androl 2003; 24 (6 Suppl.): S59–S62.
8. Moyad MA, Barada JH, Lue TF et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. Urol Clin North Am 2004; 31 (2): 249–57.
9. Moyad MA, Barada JH, Lue TF et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin North Am 2004; 31 (2): 259–73.
10. Greenstein A, Mabjeesh NJ, Sofer M et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005; 173 (2): 530–2.
11. Goldstein I, Lue TF, Padma-Nathan H et al. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol 2002; 167: 1197–203.
12. Padma-Nathan H, Stecher VJ, Sweeney M et al. Minimal time to successful intercourse after sildenafi l citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–3.
13. Carson CC, Burnett AL, Levine LA et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60: 12–27.
14. Wagner G, Montorsi F, Auerbach S et al. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001; 56: M113–9.
15. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafi l citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–5.
16. Montorsi F, Althof SE. Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 2004; 63: 762–7.
17. Gil A, Martinez E, Oyaguez I et al. Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338–47.
18. Raina R, Lakin MM, Agarwal A et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004; 63 (5): 960–6.
19. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubis prostatectomy. J Urol 2004; 171(2 Pt. 4): 771–4.
20. Padma-Nathan H, McCullough AR, Levine LA et al. Study Group. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20 (5): 479–86.
21. Shabsigh R, Rajfer J, Aversa A et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006; 60: 1087–92.
22. Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Can Urol Assoc J 2012; 6 (4): 269–74.
23. McVary KT, Monnig W, Jr Camps JL et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071–7.
24. Камалов А.А., Осмоловский Б.Е., Охоботов Д.А. и др. Комбинированное лечение больных эректильной дисфункцией, страдающих расстройствами мочеиспускания. Урология. 2013; 3: 1–4. / Kamalov A.A., Osmolovskii B.E., Okhobotov D.A. i dr. Kombinirovannoe lechenie bol'nykh erektil'noi disfunktsiei, stradaiushchikh rasstroistvami mocheispuskaniia. Urologiia. 2013; 3: 1–4. [in Russian]
25. Cantoro U, Catanzariti F, Lacetera V et al. Comparison of tamsulosin vs tamsulosin/sildenafil effectiveness in the treatment of erectile dysfunction in patients affected by type III chronic prostatitis. Arch Ital Urol Androl 2013; 85 (3): 109–12.
26. Lee KC, Brock GB. Daily dosing of PDE5 inhibitors: where does it fit in? Curr Urol Rep 2013; 14 (4): 269–78.
27. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007; 9 (1): 134–41.
28. Hatzimouratidis K (chair), Eardley I, Giuliano F et al. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. EAU Guidelines, edition presented at the 29th EAU Annual Congress, Stockholm 2014.
29. Cheitlin MD, Jr Hutter AM, Brindis RG et al. Technology and Practice Executive Committee. Use of sildenafil (Viagra) in patients with cardiovascular disease (published correction appears in Circulation 1999; 100: 2389). Circulation 1999; 99: 168–77.
30. Padma-Nathan H et al. A 4-year update on the safety of sidlenafil citrate (Viagra). Urology 2002; 60 (Suppl 2B): 67–90.
31. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622–6.
32. Carson CC III. Sildenafil: A 4-Year Update in the Treatment of 20 Million Erectile Dysfunction Patients. Curr Urol Rep 2003; 4: 488–96.
33. Giuliano F, Jackson G, Montorsi F et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64 (2): 240–55.
2. Gazzaruso C, Coppola A, Montalcini T et al. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 2011; 40 (2): 273–9.
3. Korneev I.A., Alekseeva T.A., Al'-Shukri S.Kh. i dr. Determinanty riska razvitiia erektil'noi disfunktsii muzhchin v Rossiiskoi Federatsii: analiz rezul'tatov epidemiologicheskogo issledovaniia. Urologiia. 2014; 3: 26–31. [in Russian]
4. Nehra A, Jackson G, Miner M et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87 (8): 766–78
5. Cheitlin MD. Sexual activity and cardiac risk. Am J Cardiol 2005; 96: 24M–28M.
6. Kostis J, Jackson G, Rosen R et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96 (2): 313–21.
7. Guay AT. Optimizing response to phosphodiesterase therapy: impact of risk-factor management. J Androl 2003; 24 (6 Suppl.): S59–S62.
8. Moyad MA, Barada JH, Lue TF et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. Urol Clin North Am 2004; 31 (2): 249–57.
9. Moyad MA, Barada JH, Lue TF et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin North Am 2004; 31 (2): 259–73.
10. Greenstein A, Mabjeesh NJ, Sofer M et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005; 173 (2): 530–2.
11. Goldstein I, Lue TF, Padma-Nathan H et al. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol 2002; 167: 1197–203.
12. Padma-Nathan H, Stecher VJ, Sweeney M et al. Minimal time to successful intercourse after sildenafi l citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–3.
13. Carson CC, Burnett AL, Levine LA et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60: 12–27.
14. Wagner G, Montorsi F, Auerbach S et al. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001; 56: M113–9.
15. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafi l citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–5.
16. Montorsi F, Althof SE. Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 2004; 63: 762–7.
17. Gil A, Martinez E, Oyaguez I et al. Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338–47.
18. Raina R, Lakin MM, Agarwal A et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004; 63 (5): 960–6.
19. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubis prostatectomy. J Urol 2004; 171(2 Pt. 4): 771–4.
20. Padma-Nathan H, McCullough AR, Levine LA et al. Study Group. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20 (5): 479–86.
21. Shabsigh R, Rajfer J, Aversa A et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006; 60: 1087–92.
22. Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Can Urol Assoc J 2012; 6 (4): 269–74.
23. McVary KT, Monnig W, Jr Camps JL et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071–7.
24. Kamalov A.A., Osmolovskii B.E., Okhobotov D.A. i dr. Kombinirovannoe lechenie bol'nykh erektil'noi disfunktsiei, stradaiushchikh rasstroistvami mocheispuskaniia. Urologiia. 2013; 3: 1–4. [in Russian]
25. Cantoro U, Catanzariti F, Lacetera V et al. Comparison of tamsulosin vs tamsulosin/sildenafil effectiveness in the treatment of erectile dysfunction in patients affected by type III chronic prostatitis. Arch Ital Urol Androl 2013; 85 (3): 109–12.
26. Lee KC, Brock GB. Daily dosing of PDE5 inhibitors: where does it fit in? Curr Urol Rep 2013; 14 (4): 269–78.
27. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007; 9 (1): 134–41.
28. Hatzimouratidis K (chair), Eardley I, Giuliano F et al. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. EAU Guidelines, edition presented at the 29th EAU Annual Congress, Stockholm 2014.
29. Cheitlin MD, Jr Hutter AM, Brindis RG et al. Technology and Practice Executive Committee. Use of sildenafil (Viagra) in patients with cardiovascular disease (published correction appears in Circulation 1999; 100: 2389). Circulation 1999; 99: 168–77.
30. Padma-Nathan H et al. A 4-year update on the safety of sidlenafil citrate (Viagra). Urology 2002; 60 (Suppl 2B): 67–90.
31. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622–6.
32. Carson CC III. Sildenafil: A 4-Year Update in the Treatment of 20 Million Erectile Dysfunction Patients. Curr Urol Rep 2003; 4: 488–96.
33. Giuliano F, Jackson G, Montorsi F et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64 (2): 240–55.
2. Gazzaruso C, Coppola A, Montalcini T et al. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 2011; 40 (2): 273–9.
3. Корнеев И.А., Алексеева Т.А., Аль-Шукри С.Х. и др. Детерминанты риска развития эректильной дисфункции мужчин в Российской Федерации: анализ результатов эпидемиологического исследования. Урология. 2014; 3: 26–31. / Korneev I.A., Alekseeva T.A., Al'-Shukri S.Kh. i dr. Determinanty riska razvitiia erektil'noi disfunktsii muzhchin v Rossiiskoi Federatsii: analiz rezul'tatov epidemiologicheskogo issledovaniia. Urologiia. 2014; 3: 26–31. [in Russian]
4. Nehra A, Jackson G, Miner M et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87 (8): 766–78
5. Cheitlin MD. Sexual activity and cardiac risk. Am J Cardiol 2005; 96: 24M–28M.
6. Kostis J, Jackson G, Rosen R et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96 (2): 313–21.
7. Guay AT. Optimizing response to phosphodiesterase therapy: impact of risk-factor management. J Androl 2003; 24 (6 Suppl.): S59–S62.
8. Moyad MA, Barada JH, Lue TF et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. Urol Clin North Am 2004; 31 (2): 249–57.
9. Moyad MA, Barada JH, Lue TF et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin North Am 2004; 31 (2): 259–73.
10. Greenstein A, Mabjeesh NJ, Sofer M et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005; 173 (2): 530–2.
11. Goldstein I, Lue TF, Padma-Nathan H et al. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol 2002; 167: 1197–203.
12. Padma-Nathan H, Stecher VJ, Sweeney M et al. Minimal time to successful intercourse after sildenafi l citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–3.
13. Carson CC, Burnett AL, Levine LA et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60: 12–27.
14. Wagner G, Montorsi F, Auerbach S et al. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001; 56: M113–9.
15. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafi l citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–5.
16. Montorsi F, Althof SE. Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 2004; 63: 762–7.
17. Gil A, Martinez E, Oyaguez I et al. Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338–47.
18. Raina R, Lakin MM, Agarwal A et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004; 63 (5): 960–6.
19. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubis prostatectomy. J Urol 2004; 171(2 Pt. 4): 771–4.
20. Padma-Nathan H, McCullough AR, Levine LA et al. Study Group. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20 (5): 479–86.
21. Shabsigh R, Rajfer J, Aversa A et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006; 60: 1087–92.
22. Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Can Urol Assoc J 2012; 6 (4): 269–74.
23. McVary KT, Monnig W, Jr Camps JL et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071–7.
24. Камалов А.А., Осмоловский Б.Е., Охоботов Д.А. и др. Комбинированное лечение больных эректильной дисфункцией, страдающих расстройствами мочеиспускания. Урология. 2013; 3: 1–4. / Kamalov A.A., Osmolovskii B.E., Okhobotov D.A. i dr. Kombinirovannoe lechenie bol'nykh erektil'noi disfunktsiei, stradaiushchikh rasstroistvami mocheispuskaniia. Urologiia. 2013; 3: 1–4. [in Russian]
25. Cantoro U, Catanzariti F, Lacetera V et al. Comparison of tamsulosin vs tamsulosin/sildenafil effectiveness in the treatment of erectile dysfunction in patients affected by type III chronic prostatitis. Arch Ital Urol Androl 2013; 85 (3): 109–12.
26. Lee KC, Brock GB. Daily dosing of PDE5 inhibitors: where does it fit in? Curr Urol Rep 2013; 14 (4): 269–78.
27. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007; 9 (1): 134–41.
28. Hatzimouratidis K (chair), Eardley I, Giuliano F et al. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. EAU Guidelines, edition presented at the 29th EAU Annual Congress, Stockholm 2014.
29. Cheitlin MD, Jr Hutter AM, Brindis RG et al. Technology and Practice Executive Committee. Use of sildenafil (Viagra) in patients with cardiovascular disease (published correction appears in Circulation 1999; 100: 2389). Circulation 1999; 99: 168–77.
30. Padma-Nathan H et al. A 4-year update on the safety of sidlenafil citrate (Viagra). Urology 2002; 60 (Suppl 2B): 67–90.
31. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622–6.
32. Carson CC III. Sildenafil: A 4-Year Update in the Treatment of 20 Million Erectile Dysfunction Patients. Curr Urol Rep 2003; 4: 488–96.
33. Giuliano F, Jackson G, Montorsi F et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64 (2): 240–55.
________________________________________________
2. Gazzaruso C, Coppola A, Montalcini T et al. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 2011; 40 (2): 273–9.
3. Korneev I.A., Alekseeva T.A., Al'-Shukri S.Kh. i dr. Determinanty riska razvitiia erektil'noi disfunktsii muzhchin v Rossiiskoi Federatsii: analiz rezul'tatov epidemiologicheskogo issledovaniia. Urologiia. 2014; 3: 26–31. [in Russian]
4. Nehra A, Jackson G, Miner M et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87 (8): 766–78
5. Cheitlin MD. Sexual activity and cardiac risk. Am J Cardiol 2005; 96: 24M–28M.
6. Kostis J, Jackson G, Rosen R et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96 (2): 313–21.
7. Guay AT. Optimizing response to phosphodiesterase therapy: impact of risk-factor management. J Androl 2003; 24 (6 Suppl.): S59–S62.
8. Moyad MA, Barada JH, Lue TF et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. Urol Clin North Am 2004; 31 (2): 249–57.
9. Moyad MA, Barada JH, Lue TF et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urol Clin North Am 2004; 31 (2): 259–73.
10. Greenstein A, Mabjeesh NJ, Sofer M et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005; 173 (2): 530–2.
11. Goldstein I, Lue TF, Padma-Nathan H et al. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol 2002; 167: 1197–203.
12. Padma-Nathan H, Stecher VJ, Sweeney M et al. Minimal time to successful intercourse after sildenafi l citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–3.
13. Carson CC, Burnett AL, Levine LA et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60: 12–27.
14. Wagner G, Montorsi F, Auerbach S et al. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001; 56: M113–9.
15. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafi l citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–5.
16. Montorsi F, Althof SE. Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 2004; 63: 762–7.
17. Gil A, Martinez E, Oyaguez I et al. Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338–47.
18. Raina R, Lakin MM, Agarwal A et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004; 63 (5): 960–6.
19. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubis prostatectomy. J Urol 2004; 171(2 Pt. 4): 771–4.
20. Padma-Nathan H, McCullough AR, Levine LA et al. Study Group. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20 (5): 479–86.
21. Shabsigh R, Rajfer J, Aversa A et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006; 60: 1087–92.
22. Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Can Urol Assoc J 2012; 6 (4): 269–74.
23. McVary KT, Monnig W, Jr Camps JL et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071–7.
24. Kamalov A.A., Osmolovskii B.E., Okhobotov D.A. i dr. Kombinirovannoe lechenie bol'nykh erektil'noi disfunktsiei, stradaiushchikh rasstroistvami mocheispuskaniia. Urologiia. 2013; 3: 1–4. [in Russian]
25. Cantoro U, Catanzariti F, Lacetera V et al. Comparison of tamsulosin vs tamsulosin/sildenafil effectiveness in the treatment of erectile dysfunction in patients affected by type III chronic prostatitis. Arch Ital Urol Androl 2013; 85 (3): 109–12.
26. Lee KC, Brock GB. Daily dosing of PDE5 inhibitors: where does it fit in? Curr Urol Rep 2013; 14 (4): 269–78.
27. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007; 9 (1): 134–41.
28. Hatzimouratidis K (chair), Eardley I, Giuliano F et al. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. EAU Guidelines, edition presented at the 29th EAU Annual Congress, Stockholm 2014.
29. Cheitlin MD, Jr Hutter AM, Brindis RG et al. Technology and Practice Executive Committee. Use of sildenafil (Viagra) in patients with cardiovascular disease (published correction appears in Circulation 1999; 100: 2389). Circulation 1999; 99: 168–77.
30. Padma-Nathan H et al. A 4-year update on the safety of sidlenafil citrate (Viagra). Urology 2002; 60 (Suppl 2B): 67–90.
31. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622–6.
32. Carson CC III. Sildenafil: A 4-Year Update in the Treatment of 20 Million Erectile Dysfunction Patients. Curr Urol Rep 2003; 4: 488–96.
33. Giuliano F, Jackson G, Montorsi F et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64 (2): 240–55.
Авторы
И.А.Корнеев
ГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова Минздрава России. 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8
iakorneyev@yandex.ru
ГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова Минздрава России. 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8
iakorneyev@yandex.ru
________________________________________________
I.A.Korneev
I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation. 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
iakorneyev@yandex.ru
I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation. 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
iakorneyev@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.